Benzodiazepines
Accurately detect benzodiazepine use
Benzodiazepines represent a large family of medications used to treat a wide range of disorders, from anxiety to seizures. They also are used in pain management. With a high risk for abuse and diversion, professional practice guidelines recommend compliance monitoring for these medications using urine drug tests. However, traditional benzodiazepine immunoassays suffer from a lack of cross-reactivity with many benzodiazepines.
Benzodiazepine test menu
Targeted screening
Our targeted, high-resolution mass spectrometry screening assay identifies 27 different benzodiazepines and metabolites in the urine, reducing the need for additional confirmation assays. Results of this assay enable clinicians to accurately detect recent benzodiazepine use and effectively monitor treatment compliance.
Key testing
- TBSU | Targeted Benzodiazepine Screen, Random, Urine
- Ensures adherence to federal and state regulations by:
- Monitoring compliance of patients prescribed benzodiazepines.
- Identifying potential illicit benzodiazepine use
- Ensures adherence to federal and state regulations by:
Highlights
In this “Hot Topic,” Paul Jannetto, Ph.D., highlights Mayo Clinic’s targeted benzodiazepine assay and discusses the advantages and limitations of various urine-screening assays as well as quantitative confirmatory testing to determine compliance to benzodiazepine therapy.
Comprehensive monitoring
Several of our comprehensive profiles include targeted benzodiazepine monitoring (Mayo ID: TABSU).
Panel testing
Key testing
- CSMEU | Controlled Substance Monitoring Enhanced Profile with Reflex, 21 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
- CSMHU | Controlled Substance Monitoring Hybrid Drug Profile, 20 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
- CSMTU | Controlled Substance Monitoring Targeted Profile, 17 Drug Classes, Mass Spectrometry, Random, Urine